DBVT — Q2 2026 Financial Report Analysis

DBV Technologies, the French company developing the VIASKIN Peanut skin patch for children with peanut allergy, lost $50.4 million in the second quarter of 2026, up from $41.9 million a year earlier, as it spent ahead of an FDA approval it does not yet have. It has no product revenue. The quarter's spending moved away from clinical trials and toward selling: sales and marketing costs rose from $0.4 million to $5.5 million and administrative costs from $8.5 million to $14.6 million. The planned US marketing application (a Biologics License Application, or BLA) slipped from the second quarter to the third, and was then submitted on September 29, 2026, according to an 8-K filed the next day.

At a glance

• $174.9 million in cash at June 30, down from $194.2 million at the start of the year, even though $89.0 million of new equity money came in during the half. Management says this lasts "into the third quarter of 2027".
• $101.7 million of cash used by operations in six months, nearly double the $53.6 million a year earlier. That is roughly $51 million a quarter.
• Loss per share fell 61% to $0.12 while the loss itself grew 20%. The per-share figure dropped only because the average share count more than tripled (433.5 million vs 134.5 million) after the 2025 financings.

Results for the quarter

DBV reports loss per ordinary share. Each Nasdaq-traded ADS represents five ordinary shares, so the quarter's loss works out to roughly $0.58 per ADS, against roughly $1.56 a year ago (our arithmetic from the filing's figures).

The only "income" line is France's research tax credit (crédit d'impôt recherche), a government refund for research spending. It shrank because, in the company's words, its focus "continues to shift from clinical development toward commercial readiness activities".

Where the money went

Research and development fell 7% to $31.2 million, but not because the company is doing less. Two things pulled it down:

• External clinical-trial costs dropped from $20.2 million to $16.9 million, "primarily driven by the completion of the EPOPEX study".
• "Pre-commercial inventory" — patches built ahead of a possible launch — fell from $6.0 million to $2.6 million. DBV expenses this inventory immediately because the product is not approved; if it is approved, later batches will sit on the balance sheet instead of hitting the loss.

Against that, R&D staff costs rose 58% to $8.1 million from hiring in "development, medical affairs, regulatory and quality".

Sales and marketing (+$5.1 million) and administration (+$6.1 million) are the real story. The 10-Q attributes them to "expansion of commercial, market access and launch-support capabilities" in the US and to scaling corporate infrastructure for the BLA and launch. In the first half, total operating expenses were $100.1 million, up 43% from $69.9 million. This is a company building a sales organization before it has a product to sell.

What the headline numbers hide

• The per-share improvement is dilution, not progress. Management's 10-Q says the lower loss per share "reflects a significantly strengthened equity base". Put plainly, there are far more shares sharing a bigger loss. The weighted average share count rose from 134.5 million to 433.5 million, so existing holders now own a much smaller slice of the company.
• Cash burn ran ahead of the accounting loss. Over the half, operations used $101.7 million of cash against a $98.0 million net loss. Non-cash items such as $6.0 million of share-based pay pushed the other way, so working capital (other current assets up $9.0 million, payables down $0.4 million) consumed the difference. A year ago, a $14.9 million increase in unpaid supplier bills flattered the cash figure. That makes the year-on-year jump in burn look bigger than the change in underlying spending, but the 2026 figure is the cleaner one.
• The runway claim assumes spending slows. At the first half's pace of about $51 million a quarter, $174.9 million covers about three and a half quarters, which runs out around the first quarter of 2027. Management's "into the third quarter of 2027" needs average burn of roughly $35–44 million a quarter from July 2026. The 10-Q points to "cost-containment measures" and forecasts reset after the BLA delay, and adds that the company "may end up using its resources sooner than anticipated". The going-concern basis holds for now, but only just past the twelve-month test.
• Currency cost $5.6 million of cash in the half. DBV keeps its books in euros and reports in dollars, and a large part of its costs is in euros.
• Fundraising access. In the first half, the company could not sell shares through its $150 million at-the-market program (a facility for selling shares gradually on the open market) because its shelf registration lapsed in April 2026. EDGAR shows a new automatic shelf registration (Form S-3ASR) filed on July 27, 2026, which reopens the route to raise money. With the runway above, another raise before or around an FDA decision looks likely.
• No one-offs distorted the quarter. One item to note: the balance sheet shows the accumulated deficit falling from $393.1 million to $270.3 million. This is a legal reclassification approved at the June 3 shareholder meeting, offsetting $220.8 million of past losses against share premium. It is not a profit.

Takeaway: DBV has turned into a pre-launch commercial company in its spending (sales and admin costs up $11.2 million year on year in a single quarter) while still waiting on a regulatory clock it does not control. The $174.9 million cash pile only reaches management's third-quarter-2027 target if quarterly burn falls by a quarter or more from the first half's ~$51 million.

Pipeline and regulatory picture

• BLA for ages 4–7 (VITESSE trial). VITESSE was a 654-child Phase 3 trial with positive topline results announced December 16, 2025. On June 29, 2026 DBV said the FDA had given feedback on "the organization, mapping, and formatting of existing data sets" for the manufacturing (CMC) and statistics sections. The FDA "did not request any additional data", but filing moved from Q2 to Q3. The 8-K of September 30, 2026 confirms submission, with Priority Review requested. The product already has Breakthrough Therapy Designation.
• Toddlers (ages 1–3). A Phase 3 supplementary safety study (COMFORT Toddlers) is ongoing. The 10-Q plans a second BLA in the second half of 2026, "conditional on successful completion" of that study.
• Infants. The Phase 2 THRIVE study (ages 6–12 months, 36 months of treatment) screened its first participant in June 2026.
• Manufacturing risk. The 10-Q adds a new risk factor. The FDA has issued warning letters to Fareva Amboise, DBV's sole patch manufacturer, citing manufacturing-quality (cGMP) deficiencies, including at the facility that makes VIASKIN Peanut. DBV says it has no ready alternative supplier. Separately, it signed a letter of intent with Fareva in June for commercial-scale production (an estimated $7.5 million investment, up to $5.2 million supported by DBV), and a letter of intent with ICS for US distribution.

Outlook

Management gave no financial guidance beyond the runway statement. What decides the next twelve months:

1. FDA acceptance of the BLA, normally within about 60 days of submission, so around late November 2026, and whether Priority Review is granted. Priority Review would put a decision about six months after acceptance rather than ten. Part of the CEO's new performance-based stock award is tied to FDA acceptance.
2. Whether Fareva fixes its warning-letter issues. An approval decision depends on the plant passing inspection as much as on the trial data.
3. Third-quarter cash burn (10-Q expected around late October). It needs to come down toward ~$40 million for the runway guidance to look comfortable. If it does not, expect an equity raise using the new shelf.

Our read: the clinical case has been made and the remaining risks are regulatory, manufacturing and financing, not scientific. Shareholders should expect further dilution before any revenue arrives.